Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer

Cancer Biology and Therapy

Volumn 12, Issue 9, 2011, Pages 808-817

  Rosca, Elena V ^a   Koskimaki, Jacob E ^a   Pandey, Niranjan B ^a   Wolff, Antonio C ^b   Popel, Aleksander S ^a,b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer therapy; Drug development; Integrins; Triple negative; Xenograft

Indexed keywords

ACTIN; BUTYRIC ACID; COLLAGEN TYPE 4; CYSTEINE DERIVATIVE; PACLITAXEL; PEPTIDE DERIVATIVE; SP 2000; SP 2012; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOMIMETICS; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FAMILY; TUMOR GROWTH; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANGIOGENESIS INHIBITORS; ANIMALS; BIOMIMETICS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN TYPE IV; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RECEPTORS, CELL SURFACE; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80655141263     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.9.17677     Document Type: Article

References (37)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-6; PMID:16355210; DOI:10.1038/nature04478.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57; PMID:11001068; DOI:10.1038/35025220.
3. Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1-18; PMID:16409133; DOI:10.1146/annurev.med.57.121304.131306.
4. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005; 65:5144-52; PMID:15958558; DOI:10.1158/0008-5472.CAN-04-3744.
5. Clamp AR, Jayson GC. The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer 2005; 93:967-72; PMID:16234821; DOI:10.1038/sj.bjc.6602820.
6. Nakamura T, Matsumoto K. Angiogenesis inhibitors: from laboratory to clinical application. Biochem Biophys Res Commun 2005; 333:289-91; PMID:15953588; DOI:10.1016/j.bbrc.2005.06.001.
7. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65:3967-79; PMID:15899784; DOI:10.1158/0008-5472.CAN-04-2427.
8. Rosca EV, Koskimaki J, Pandey N, Rivera C, Tamiz A, Popel A. Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 2011; 12:1101-16; PMID:21470139; DOI:10.2174/138920111796117300.
9. Gressett SM, Shah SR. Intricacies of bevacizumab- induced toxicities and their management. Ann Pharmacother 2009; 43:490-501; PMID:19261963; DOI:10.1345/aph.1L426.
10. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009; 73:1200-6; PMID:19822869; DOI:10.1212/WNL. 0b013e3181bc0184.
11. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76; PMID:18160686; DOI:10.1056/NEJMoa072113.
12. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer 2009; 52:169-76; PMID:19065567; DOI:10.1002/pbc.21873.
13. Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, et al. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res 2010; 30:2335-9; PMID:20651389.
14. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28:780-7; PMID:20048182; DOI:10.1200/JCO.2009.23.7537.
15. Karagiannis ED, Popel AS. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA 2008; 105:13775-80; PMID:18780781; DOI:10.1073/pnas.0803241105.
16. Saladin PM, Zhang BD, Reichert JM. Current trends in the clinical development of peptide therapeutics. IDrugs 2009; 12:779-84; PMID:19943221.
17. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis and optimization of pharmacokinetics and biological activities. J Med Chem 2005; 48:2838-46; PMID:15828822; DOI:10.1021/jm0401560.
18. Mahalakshmi R, Balaram P. Non-protein amino acids in the design of secondary structure scaffolds. Methods Mol Biol 2006; 340:71-94; PMID:16957333.
19. Oscarsson K, Poliakov A, Oscarson S, Danielson UH, Hallberg A, Samuelsson B. Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease- helicase/NTPase): model compounds towards small molecule inhibitors. Bioorg Med Chem 2003; 11:2955-63; PMID:12788365; DOI:10.1016/S0968-0896(03)00190-1.
20. Tran TT, Treutlein H, Burgess AW. Designing amino acid residues with single-conformations. Protein Eng Des Sel 2006; 19:401-8; PMID:16799150; DOI:10.1093/protein/gzl024.
21. Geotti-Bianchini P, Moretto A, Peggion C, Beyrath J, Bianco A, Formaggio F. Replacement of Ala by Aib improves structuration and biological stability in thymine- based alpha-nucleopeptides. Org Biomol Chem 2010; 8:1315-21; PMID:20204202; DOI:10.1039/b920211k.
22. Karim CB, Paterlini MG, Reddy LG, Hunter GW, Barany G, Thomas DD. Role of cysteine residues in structural stability and function of a transmembrane helix bundle. J Biol Chem 2001; 276:38814-9; PMID:11477077; DOI:10.1074/jbc. M104006200.
23. Hendrickson TL, de Crecy-Lagard V, Schimmel P. Incorporation of nonnatural amino acids into proteins. Annu Rev Biochem 2004; 73:147-76; PMID:15189139; DOI:10.1146/annurev.biochem.73.012803.092429.
24. Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/ Ala2 with 2-aminobutyric acid. Arch Biochem Biophys 2004; 428:136-43; PMID:15246869; DOI:10.1016/j.abb.2004.05.005.
25. Mallik B, Katragadda M, Spruce LA, Carafides C, Tsokos CG, Morikis D, et al. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem 2005; 48:274- 86; PMID:15634022; DOI:10.1021/jm0495531.
26. Koskimaki JE, Karagiannis ED, Rosca EV, Vesuna F, Winnard PT Jr, Raman V, et al. Peptides derived from type IV collagen, CXC chemokines and thrombospondin- 1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia 2009; 11:1285-91; PMID:20019836.
27. Arnaoutova I, George J, Kleinman HK, Benton G. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 2009; 12:267-74; PMID:19399631; DOI:10.1007/s10456-009-9146-4.
28. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 2006; 5:933-40; PMID:16775428; DOI:10.4161/cbt.5.8. 2875.
29. Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, et al. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer 2010; 10:29; PMID:20122172; DOI:10.1186/1471-2407-10-29.
30. Goodwin AM. In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 2007; 74:172-83; PMID:17631914; DOI:10.1016/j.mvr.2007.05.006.
31. Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D, Galper JB. Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev 2006; 2:93-102; PMID:17237547; DOI:10.1007/s12015- 006-0015-x.
32. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004; 3:1301-10; PMID:15486197.
33. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008; 7:3670-84; PMID:19074844; DOI:10.1158/1535-7163.MCT-08-0715.
34. Wong ST. Emerging treatment combinations: integrating therapy into clinical practice. Am J Health Syst Pharm 2009; 66:9-14; PMID:19923318; DOI:10.2146/ajhp090439.
35. Greenberg S, Rugo HS. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J 2010; 16:33-8; PMID:20164688; DOI:10.1097/ PPO.0b013e3181d38514.
36. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Smith DC, Small E, et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs 2010; 29:1432-40. PMID: 20336348; DOI: 10.1007/s10637-010-9420-8
37. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009; 15:392-400; PMID:19305413; DOI:10.1038/nm.1941.